Oneview Healthcare PLC reported a 13% year-over-year increase in recurring revenue for the first half of fiscal 2026, as gross margins expanded to 70% from 61% in the same period last year.
Total revenue declined 14% on a reported basis and 9% in constant currency, reflecting a EUR 1.3 million drop in non-recurring revenue. Recurring revenue now represents 79% of total sales, up from 60% in H1 2025. Gross profit remained roughly flat at EUR 3.8 million, while the operating EBITDA loss narrowed 11% to EUR 4 million.
Cash operating expenses fell 6% year-over-year, and operating cash burn decreased 15%. The company held EUR 7.2 million in cash as of June 30, with a pending EUR 4.2 million capital raise subject to shareholder approval at the upcoming AGM. Including the pending tranche, the pro forma cash balance stood at EUR 11.4 million.
Shares of Oneview rose 6.25% to $0.17 following the release, narrowing the 52-week range to between $0.13 and $0.41. The stock’s beta stands at 0.96.
Chief Executive Officer James Fitter highlighted the shift toward recurring revenue, stating it grew 13% year-over-year. He also noted the nine-percentage-point gross margin improvement and the company’s increasing reliance on AI-driven development, with 85% of code now written by AI agents under human supervision. Feature development speed has accelerated by approximately 170% based on story points delivered.
The company’s Bedside Hub product, aligned with Epic’s bedside TV strategy, has secured 16 opportunities covering over 20,000 beds. Management aims to win 3 to 4 additional contracts before year-end. Epic’s dominance in U.S. acute care—accounting for 43% of hospitals and 56% of beds—positions Oneview to leverage large-scale deployments, which can cost up to EUR 1 billion per Epic instance.
Customer renewals have included pricing increases of 15% to 20%, reflecting the growing value of the platform. The company completed a global restructuring in June 2025 and now operates with 15,010 live endpoints as of June 30.
